Optimal biomarker combinations for treatment-selection can be derived by minimizing total burden to the population caused by the targeted disease and its treatment. However, when multiple biomarkers are present, including all in the model can be expensive and hurt model performance. To remedy this, we consider feature selection in optimization by minimizing an extended total burden that additionally incorporates biomarker measurement costs. Formulating it as a 0-norm penalized weighted classification, we develop various procedures for estimating linear and nonlinear combinations. Through simulations and a real data example, we demonstrate the importance of incorporating feature-selection and marker cost when deriving treatment-selection rules.